2022 Year In Review for investor audiences

Regeneron leaders reflect on 2022 accomplishments. Learn more about our approved medicines, including Prescribing Information.

For 35 years, Regeneron has remained steadfast in our mission to use the power of science to repeatedly bring new, life-transforming medicines to patients.

Our products and pipeline are designed to help patients across many disease areas, and we are always looking for ways to accelerate and improve the traditional drug development process through our innovative technologies and ambitious research initiatives.

From conducting one of the world’s largest genetics sequencing efforts, to expanding on our proprietary VelociSuite® technologies, to advancing novel and investigational bispecific antibodies, we are applying our homegrown tools and relentless spirit to discover new targets and potential treatments, advance our clinical studies and help reach people with serious diseases around the world.

Regeneron employees engaged in community initiative.


Corporate responsibility is at the heart of everything we do and every decision we make. At Regeneron, we use our unique knowledge and expertise to improve the lives of people with serious diseases, as well as to benefit society, the economy and our environment. We apply our science-led approach to advance our global 2025 responsibility goals, foster a culture of integrity and excellence and build sustainable communities. By addressing issues that matter most to our business and society, we are working toward building resiliency and improving our world. Go deeper in our 2022 Responsibility Report.

Proxy Statement and Notice of Annual Shareholder Meeting 2023.


Learn more about our annual updates for 2023 in our Proxy.


This Year in Review contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Please see Regeneron’s press release announcing its financial and operating results for the fourth quarter and full year 2022 for important information about Regeneron’s forward‑looking statements.